title: Immune status in congenital infections by TORCH agents in pregnant Thais.
abstract: A cross-sectional, sero-epidemiological survey of the prevalence of antibodies to TORCH agents during various stages of gestation revealed an overall rate of 13-15 percent having antibodies to Toxoplasma gondii; 85-87 percent, to rubella ; 79-81 percent, to herpes simplex virus (HSV); 100 percent, to cytomegalovirus (CMV); 82-86 percent, to human herpes virus type 6 (HHV-6); 1-2 percent, to hepatitis C virus (HCV). None of human T lymphotropic virus type I (HTLV-I) antibody was detected, and a prevalence of hepatitis B surface antigen (HBsAg) was 6 percent. Although a tendency was noted towards an increase of antibody detection to each TORCH agent as gestation progressed, a statistically significant increase in antibodies titer and specific IgM antibody was found with regard to CMV. These results suggest an increase in CMV infection or reactivation during pregnancy whereas an increase in the other TORCH infections was not obvious.
authors.affiliation: Department of Biology, Faculty of Science, Silpakorn University, Nakorn Pathom, Thailand.
authors.forename: T
authors.initials: T
authors.lastname: Taechowisan
authors.forename: R
authors.initials: R
authors.lastname: Sutthent
authors.forename: S
authors.initials: S
authors.lastname: Louisirirotchanakul
authors.forename: P
authors.initials: P
authors.lastname: Puthavathana
authors.forename: C
authors.initials: C
authors.lastname: Wasi
mesh_terms: D000293:Adolescent; D000328:Adult; D000913:Antibodies, Protozoan / Q000032:analysis; D000914:Antibodies, Viral / Q000032:analysis; D003430:Cross-Sectional Studies; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000276:immunology; D005260:Female; D015490:HTLV-I Infections / Q000175:diagnosis / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000175:diagnosis / Q000276:immunology; D006561:Herpes Simplex / Q000175:diagnosis / Q000276:immunology; D006566:Herpesviridae Infections / Q000175:diagnosis / Q000276:immunology; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis / Q000276:immunology; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000453:epidemiology* / Q000469:parasitology / Q000821:virology; D011261:Pregnancy Trimester, First / Q000276:immunology; D011262:Pregnancy Trimester, Second / Q000276:immunology; D011263:Pregnancy Trimester, Third / Q000276:immunology; D015995:Prevalence; D012409:Rubella / Q000175:diagnosis / Q000276:immunology; D016036:Seroepidemiologic Studies; D013785:Thailand / Q000453:epidemiology; D014123:Toxoplasmosis / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology; D014777:Virus Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology
chemical_list: D000913:Antibodies, Protozoan; D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens; D007075:Immunoglobulin M